Skip to content

YNIOS Pharma

Active Private limited companyfounded 2022active for 4 yearsAvenue Wolfers 32, 1310 La HulpeKBO/BCE: BE 0783.494.239 subsidiary of

Lifetime

4 annual accounts with figures on one time axis
peak of €392,886 in 2024
-€4,809▼ €397,695
lowest -€228,903 in 2025
-€228,903▼ €571,027
peak of €702,466 in 2024
€473,563▼ 32.6%
€320,896▲ 19.8%
Board2 names since 2022
2 directors and 1 other
Documentsfilings and deeds
12-06-202649 days before the deadline
2025micro format
Gross margin from €392,886 to -€4,809Loss of €228,903Equity from €702,466 to €473,563Debts from €267,824 to €320,896Cash from €257,192 to €4,753

Key points

from the 2025 annual accounts

Result

-€228,903 -€228,903
€342,0002024-€229,0002025

From profit to loss in 2025, after a profit of €342,124 in 2024.

Investments

€193,754 1.7 times depreciation
2022202320242025

Green is investment, beige is depreciation.

Liquidity

0.04 was 0.99 in 2024

Short-term debts rose from €267,824 to €320,896.

Filings

4 annual accounts 1 late
AprilJune31 JulyOctober2022202320242025

The 2024 accounts came 1 day late. The other three were filed on time.

Position in the sector

-€228,903

Lower net result than 95% of companies in chemicals. Sector median €201 · 168 companies.

Turnover not published in the micro format

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 132 companies had the same profile as YNIOS Pharma has now. Each dot is one company, two years later.

93.2%
were still trading
3.8%
stopped another way
3.0%
went bankrupt
  • Small
  • 2 to 5 years old
  • solvency 30% or more
  • a loss of 10% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 132 companies, not a prediction for YNIOS Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director,
  • 100%equity €61,500 (2025) · deed of 28-09-2022
Board & ownership

Recent changes

Registered office moved from Verlaine to La Hulpe The registered office moved from 6-C Chemin de I'Yerne, 4537 Verlaine, Belgique to 32 Avenue Wolfers, 1310 La Hulpe, Belgique · acts as permanent representative · Board meeting of 21-05-2026 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0783494239
Share issue · Amendment of the articles Issue of 74,500 shares · General meeting of 08-08-2024 · Gazette deed
Share issue · Amendment of the articles Issue of 7,600 shares · Issue of 87,400 shares · Issue of 2,700 shares · General meeting of 19-03-2024 · Gazette deed
All 15 events

Comparable companies

same main activity, similar in size and age
Company
YNIOS Pharma La Hulpe €0.8m -€4,809 59.6% -
LABO DéESSE Beveren-Kruibeke-Zwijndrecht €0.8m -€9,860 -12.5% -
Le Rub Antwerp €0.4m -€273,339 -260.0% -
LABORATOIRES DE BIARRITZ INTERNATIONAL Waterloo €2.3m -€27,119 -59.9% 1
BESTIALE MAKEUP Ans €0.2m -€69,865 -46.4% -
LA MAISONNETTE Welkenraedt €0.2m -€78,703 -138.3% -
CONBIN Wevelgem €0.5m €10,178 35.6% 0

These companies have the same main activity as YNIOS Pharma: manufacture of chemicals and chemical products (NACE 20420). They are comparable in size and age: total assets between €211,000 and €2.3m, founded between 2017 and 2024.

Official details

Source: KBO
Status
Active since 16-03-2022Normal situation
Activity
Manufacture of chemicals and chemical productsNACE 20420and 2 others
Financial year end
31 December
Peppol
Reachable since 28-01-2026
Company details

Annual accounts 2025

€794,459▼ 18.1%
Filing
Filed on 12-06-2026, 49 days before the end of the filing period
Financials

Companies linked to YNIOS Pharma

Parent and group

Insights on YNIOS Pharma

YNIOS Pharma files the micro format. That format states no turnover. The gross margin rose from -€133,591 in 2022 to -€4,809 in 2025.

holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about YNIOS Pharma

What is the company number of YNIOS Pharma?
The company number of YNIOS Pharma is 0783.494.239. The VAT number is the same number with BE in front: BE 0783.494.239.
Where is YNIOS Pharma based?
The registered office is at Avenue Wolfers 32, 1310 La Hulpe.Company details
What does YNIOS Pharma do?
According to the KBO register, the main activity is manufacture of chemicals and chemical products (NACE 20420).
What is the legal form of YNIOS Pharma?
YNIOS Pharma is a private limited company (BV).
When was YNIOS Pharma founded?
YNIOS Pharma was founded on 16-03-2022.
Is YNIOS Pharma still active?
Yes, YNIOS Pharma is an active enterprise in the KBO register.
What is the turnover of YNIOS Pharma?
The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
Is YNIOS Pharma profitable?
In financial year 2025, YNIOS Pharma made a loss of €228,903.
Where can I find the annual accounts of YNIOS Pharma?
YNIOS Pharma filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of YNIOS Pharma due?
YNIOS Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.